Pyoderma gangrenosum associated with dulaglutide therapy

Int J Dermatol. 2019 Oct;58(10):1202-1204. doi: 10.1111/ijd.14272. Epub 2018 Oct 21.

Authors

Carsten R Hamann¹, Catherine Chung^{2

3}, Benjamin H Kaffenberger³

Affiliations

¹ Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
² Department of Pathology, The Ohio State University, Columbus, OH, USA.
³ Division of Dermatology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

PMID: 30345551
DOI: 10.1111/ijd.14272

No abstract available

Publication types

Case Reports

MeSH terms

Adalimumab / therapeutic use
Biopsy
Cyclosporine / therapeutic use
Diabetes Mellitus, Type 2 / drug therapy*
Drug Therapy, Combination / methods
Female
Glucagon-Like Peptides / adverse effects
Glucagon-Like Peptides / analogs & derivatives*
Humans
Hypoglycemic Agents / adverse effects*
Immunoglobulin Fc Fragments / adverse effects*
Injections, Intralesional
Middle Aged
Pyoderma Gangrenosum / chemically induced*
Pyoderma Gangrenosum / diagnosis
Pyoderma Gangrenosum / drug therapy
Recombinant Fusion Proteins / adverse effects*
Skin / drug effects
Skin / pathology
Treatment Outcome
Triamcinolone / administration & dosage

Substances

Hypoglycemic Agents
Immunoglobulin Fc Fragments
Recombinant Fusion Proteins
Triamcinolone
Glucagon-Like Peptides
Cyclosporine
Adalimumab
dulaglutide